Intravitreal anti-VEGF agents are linked to a slight increase in the risk for stroke in patients with age-related macular degeneration, but only for about 2 months after the last injection.

Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI ...

Explore the evolving RVO treatment landscape from anti-VEGF breakthroughs to pipeline innovations addressing unmet needs in efficacy, safety, and dosing burden. Retinal Vein Occlusion care is entering ...

To evaluate long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in the Netherlands (NL), where bevacizumab is the mandated first-line drug, compared to high ...

Alternative anti-VEGF regimens have been employed to decrease the number and frequency of intravitreal injections to allow discontinuation of treatment upon cessation of disease activity, and to ...

Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Shifa Trust (AST) has expressed profound concern over the escalating threat of Diabetic Retinopathy, attributing the rise to ...

- No intervention was shown to perform better for the treatment of central serous chorioretinopathy (CSC) than another. - Larger and higher-quality studies are needed to assess the benefits and ...

Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase ...

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses the impact of wet age-related macular ...

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer ...